

Docket No.: ENP-036  
Serial No.: TBD

1010071235

1626  
RECEIVED  
FEB 04 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Yat Sun Or *et al.*  
U.S. Appl. Serial No.: TBD  
Filing date: October 22, 2001  
Group Art Unit: TBD  
Examiner: TBD  
Title: Alpha- Hydroxyarylbutanamine Inhibitors of Aspartyl Protease

Certificate of Mailing under 37 C.F.R. § 1.8(a)

I hereby certify that this correspondence is being deposited today with the United States Postal Service as First Class Mail in an envelope addressed to: Box DD, Commissioner for Patents, Washington, D.C. 20231.

Stacie Capotosto  
Date: 12/18/01

INFORMATION DISCLOSURE STATEMENT

Box DD  
Commissioner for Patents  
Washington, D.C. 20231

Dear Sir/ Madam:

In accordance with the provisions of 37 C.F.R. §§ 1.56, 1.97 and 1.98 in the aforementioned matter, Applicants wish to bring to the Examiner's attention the following references, references AA, AB, CA, CB, CC, CD and CE, cited on the attached Form PTO-1449 (Rev. 2-32):

- 1) U.S. Patent No. 5,484,926 (ref. AA);
- 2) U.S. Patent No. 5,585,397 (ref. AB);
- 3) Jungheim *et al.*; *Journal of Medicinal Chemistry*, 1996, Vol. 39, No.1, Pages 96-108 (ref. CA);
- 4) Kaldor *et al.*; *Journal of Medicinal Chemistry*, 1997, Vol. 40, No. 24, Pages 3979-3985 (ref. CB);
- 5) Branalt *et al.*; *Tetrahedron Letters*, 1997, Vol.38, No. 19, Pages 3483-3486 (ref. CC);

Doc. No. ENP-036  
Serial No. TBD

- 6) Beaulieu *et al.*; *J. Org. Chem.*, 1997, Vol.62, No. 11, Pages 3440-3448 (ref. CD); and
- 7) Beaulieu *et al.*; *Journal of Medicinal Chemistry*, 2000, Vol. 43, No. 6, Pages 1094-1108 (ref. CE).


In accordance with the provisions of 37 C.F.R. § 1.97, this statement is being filed:

- ☒ (1) **within three (3) months of the Filing Date** or before the mailing date of the First Office Action on the merits; or
- ☐ (2) within three months of the mailing date of the PCT International Search Report; or
- ☐ (3) after the period defined in (1) but before the mailing date of a Final Rejection or Notice of Allowance, and the requisite Certification or fee under Rule 1.17(p), namely \$ 180.00, is included herein; or
- ☐ (4) after the mailing date of a Final Rejection or Notice of Allowance but before the payment of the Issue Fee, and the requisite Certification, petition, and petition fee are included herein.

It is respectfully requested that each of the documents shown on the attached Form PTO-1449 (Rev. 2-32) be made of record in this application. Copies of these documents (CHECK ONE):

- ☒ are enclosed herewith; or
- ☐ have been cited in an earlier related application, and need not be submitted herein (courtesy copy enclosed).

Respectfully Submitted by,

  
Sandhya Kalkunte  
Registration No. 46,466

Enanta Pharmaceuticals, Inc.  
Tel: (617) 607-0747  
Fax: (617) 607-0535  
Date: December 18, 2001